The Delegation of the European Union to the USA cordially invites you to an information and networking event on

Horizon 2020: Work Programme for 2016-2017

on

Wednesday, 9 December 2015 from 2:00pm to 5:00pm

at the

Delegation of the European Union to the USA
2175 K Street, NW – Washington D.C. (use entrance on 22nd Street)

Please RSVP by 7 December to delegation-usa-era@eeas.europa.eu

This event is free but registration is required to attend as seating is limited. Networking reception follows the presentation.
Agenda

2:00pm – 2:05pm  Welcoming remarks

2:05pm – 2:35pm  Overview of Horizon 2020 and its Work Programme for 2016-2017 -
James P. Gavigan, PhD, Minister Counselor, Head of the Science, Technology and Innovation Section, Delegation of the European Union to the USA

2:35pm – 2:50pm  A U.S. Perspective on participating in Horizon 2020 -
Jesse J.K. Szeto, Senior Manager, NCURA Global, National Council of University Research Administrators
(NCURA acted as the U.S. National Contact Point (NCP) for legal and financial issues for Horizon 2020 on a pilot basis until end October 2015)

2:50pm – 3:00pm  Testimonial: Experience with the Horizon 2020 project EUNCL –
European Nanomedicine Characterization Laboratory – Scott E. McNeil, PhD, Director of the Nanotechnology Characterization Laboratory (NCL), National Cancer Institute

3:00pm – 3:30pm  Discussion, Q/A with the audience

3:30pm – 5:00pm  Networking reception

Horizon 2020 is the European Union's main instrument for funding research and innovation activities from 2014 to 2020. It focuses on three overarching priorities – excellent science, industrial leadership and societal challenges. Horizon 2020 is open to participants from anywhere in the world.

Funding opportunities under Horizon 2020 are set out in biennial work programmes which cover the majority of support available. These work programmes are prepared by the European Commission. The new work programme for 2016-2017 adopted on October 13, 2015 will give rise to an EU contribution of almost €16 billion to research and innovation investment over the next two years.

During the presentations the main elements of Horizon 2020 will be described in terms of content, types of activities funded, forms of participation, the rules which apply, etc. The different types of international cooperation which Horizon 2020 can accommodate – at individual researcher, collaborative project or program level will also be described.

James P. Gavigan, PhD - James has been an official of the European Commission since 1990. Since September 2012, he has been Minister-Counsellor and Head of the Science, Technology and Innovation section at the European Union’s Delegation to the United States of America in Washington DC. His main role is to facilitate scientific cooperation between the EU and the US at both government-agency and stakeholder levels. Current priorities include marine/Arctic sciences, materials, health and transportation research as well as innovation-related aspects of other EU-US areas of policy dialogue - e.g. the Transatlantic Trade and Investment Partnership. He also oversees cooperation between US-based EU Member State Science Counsellors, undertakes outreach and promotional activities as well as fulfilling regular Counsellor duties. Prior to his posting to the US, James worked in a number of different EU science policy positions including eight and a half years (1995-2003) at the Institute for Prospective Technological Studies in Seville, Spain and six years (2006-2012) as Head of the European Commission’s European Research Area (ERA) Policy Unit. From 1985 to 1990, he worked as a research physicist mainly in Ireland and France. James has bachelor's (1985) and doctoral degrees in physics (1988) from Trinity College Dublin, and a master's in public administration (2003) from the University of Warwick.

Jesse J.K. Szeto - Jesse J.K. Szeto is the Senior Manager for Global Operations at the National Council of University Research Administrators (NCURA), and he also served as the Horizon 2020 National Contact Point for Legal and Financial Affairs for the U.S. He has been a university administrator in both the University of Wisconsin and the University of California, and he has also managed economic and social development projects for the State of California and the United Nations. He also currently serves as U.S. Advisor to Sri Lanka-based Verité Research, an economic and governance think tank. He had also previously served as project management expert for a SIDA (Swedish International Development Cooperation Agency)-funded project in 13 countries in Africa and Asia and had been a management consultant to the government of Abu Dhabi and to Fortune 500 companies. He received his Master’s degree in International Development from the International University of Japan (国際大学) and his Bachelor’s degree in East Asian Studies from Harvard University.

Scott E. McNeil, PhD - Dr. McNeil serves as the Director of the Nanotechnology Characterization Laboratory (NCL) for Leidos Biomedical Research and Frederick National Laboratory for Cancer Research, where he coordinates preclinical characterization of nanotech cancer therapeutics and diagnostics. At the NCL, Dr. McNeil leads a team of scientists responsible for testing candidate nanotech drugs and diagnostics, evaluating safety and efficacy, and assisting with product development -- from discovery-level, through scale-up and into clinical trials. NCL has assisted in characterization and evaluation of more than 300 nanotechnology products, several of which are now in human clinical trials. Dr. McNeil is a member of several working groups on nanomedicine, environmental health and safety, and other nanotechnology issues. He is an invited speaker to numerous nanotechnology-related conferences and has several patents pending related to nanotechnology and biotechnology. He is also a Vice President of Leidos Biomedical Research. Prior to establishing the NCL, he served as a Senior Scientist in the Nanotech Initiatives Division at Leidos where he transitioned basic nanotechnology research to government and commercial markets. He advises industry and State and US Governments on the development of nanotechnology and is a member of several governmental and industrial working groups related to nanotechnology policy, standardization and commercialization. Dr. McNeil's professional career includes tenure as an Army Officer, with tours as Chief of Biochemistry at Tripler Army Medical Center, and as a Combat Arms officer during the Gulf War. He received his bachelor's degree in chemistry from Portland State University and his doctorate in cell biology from Oregon Health Sciences University.